Publication Date

2011

Abstract

The value of β-blockers in cardiology is well established. β-blockers were first shown to improve outcomes, including recurrent infarction, after myocardial infarction ( MI ) in the early 1980s, before the value of antiplatelet therapy, angiotensin-converting-enzyme inhibitors, and statins was known.

School/Institute

Mary MacKillop Institute for Health Research

Document Type

Journal Article

Access Rights

ERA Access

Access may be restricted.

Share

COinS